Shop

Author at Microdose

Jason Najum

Jason Najum's work has appeared in many industry-leading publications, covering topics ranging from cleantech start-ups to travel and culture. He's currently Microdose's Managing Editor and Senior Writer. Write him at jason@microdose.buzz and see his work at www.jasonnajum.com

Breaking News, Industry

22 Jun 2023

MindMed Survives Takeover Attempt: Shareholders Reject FCM Board Candidates

MindMed shareholders have voted to elect all 6 of the company’s proposed board members — rejecting the candidates from activist investors....

By Jason Najum

Culture

19 Jun 2023

Celebrity Update: CNN & Oprah Talk Psychedelic Healing

Celebrities and major media publications continue to talk about the potential of psychedelics. Now CNN and Oprah Winfrey have joined the club....

By Jason Najum

Law & Politics

15 Jun 2023

Republican Lawmakers Introduce New Bill for Psychedelic Therapy

On Wednesday, Republican lawmakers and former military veterans spoke to the public about the benefits of psychedelic medicine and a new psychedelic therapy bill...

By Jason Najum

Science

7 Jun 2023

Study Shows New Mechanism For How Psychedelics Promote Plasticity

A study published in Nature shows potential new way for how psychedelics act on the brain and promote plasticity...

By Jason Najum

Join Our Newsletter for Exclusive Updates, Stories, and More

Industry

1 Jun 2023

Compass Pathways’ COMP360 Produces 50% Long-Term Depression Remission in Cancer Patients

Late last week we received news that Compass Pathways' psilocybin compound COMP360 produced extremely positive results in alleviating depression results in cancer patients....

By Jason Najum

Breaking News

25 May 2023

MindMed Publishes Report by FDA Experts: Is FCM’s Takeover Attempt Over?

A group of activist investors are trying to take control of MindMed’s board of directors. Today, MindMed has pushed back, potentially dealing a final blow to this increasingly suspect attempted...

By Jason Najum

Industry

11 May 2023

$3,500: The Cost of Treatment in America’s First Legal Psilocybin Center

Oregon has just opened the US's first licensed treatment center. Prices hit $3,500 per treatment. This is a first look at the financial realities facing providers and patients....

By Jason Najum

Industry

3 May 2023

MindMed Drama: Freemans Attempt Board of Directors Takeover

The drama continues at MindMed. The (former?) fan-favorite has had a rough run, facing an industry-wide drop in share price while dealing with a string of scenarios that have (rightly...

By Jason Najum

Science

28 Apr 2023

atai Life Sciences Presents Phase 1 Study Data on GRX-917

Earlier this year, atai Life Science company GABA Therapeutics announced Positive Final Results from Phase 1 trial of GRX-917....

By Jason Najum

Follow us on social

Latest News

Reading the Brain’s Response: Enveric’s EB-003 Takes a Step Toward Human Testing

The Cost of Waiting: What Compass’s Depression Survey Means for Psychedelic Medicine

Beyond the Psychedelic Experience: Enveric Biosciences Takes Another Step Toward a New Generation of Mental Health Treatments

You Might Also Like

11 Aug 2026

Enveric Biosciences Adds Another Data Point to Its Case That EB-003 Won’t Get You High

Enveric Biosciences is trying to answer one of the trickiest questions in the psychedelic drug space: can you get the antidepressant benefits people associate with psychedelics without the trip? On...

By Madison Roberts

28 Jul 2026

FDA’s New Psychedelic Guidance Signals a Maturing Industry. Now Comes the Hard Part.

For years, the psychedelic medicine industry has operated in largely uncharted regulatory territory. Companies developing psilocybin, LSD, MDMA, and next-generation psychedelic-inspired compounds have often found themselves navigating a clinical landscape...

By Madison Roberts

13 Jul 2026

The Psychedelic Sector Has Grown Up. Wall Street Just Hasn’t Fully Realized It Yet

The sector experienced an early wave of enthusiasm fueled by bold promises, lofty valuations, and the belief that psychedelic medicine would quickly transform mental healthcare. Reality, however, proved more complicated....

By Madison Roberts

28 May 2026

Medical Psilocybin Act

New York lawmakers are officially considering the “Medical Psilocybin Act,” legislation that would create legal access to psilocybin therapy for conditions like PTSD, treatment-resistant depression, substance use disorders, end-of-life distress,...

By Madison Roberts

5 May 2026

PTSD, Policy Shifts, and the Rise of Neuroplastogens: What Enveric’s Latest Data Signals for the Field

By Madison Roberts

21 Apr 2026

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

President Donald Trump’s April 2026 executive order on accelerating treatments for serious mental illness does something the psychedelic industry has been waiting for, and quietly fearing. It removes ambiguity. For...

By Madison Roberts
WordPress Ads
No Result
View All Result

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.